AGEN
AGENUS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Dec 4 ▼ Agenus Inc. and its CEO Garo Armen had their answers stricken and de…
- May 11 ▲ Agenus reported Q1 2026 total revenue of $33.7M (up from $24.1M YoY)…
- Jul 13 ▼ Agenus entered into a securities purchase agreement for a ~$85M PIPE…
- Aug 7 ▼ Agenus filed a resale registration statement on Form S-3 to register…
- Sep 3 Trial readout: T-90d Trial Readout: CR6086 (Phase 2)
- Sep 8 Trial readout: T-90d Trial Readout: CR6086 (Phase 2)
- Sep 18 Chardan Capital initiates
- Sep 28 Rodman & Renshaw initiates
- Nov 6 ▲ Earnings: AGEN Q3 2026 Earnings: EPS $0.02 (+107.3% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 22 added (1 new), 10 trimmed or exited.
- AnalystsBULLISH
8 of 9 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.040 → −$0.220 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +8.5% to 7.60M shares. 10.7 days to cover, ≈16.8% of shares.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | ADD | $7.8M |
| STATE STREET CORP | ADD | $7.5M |
| MORGAN STANLEY | ADD | $3.8M |
| UBS Group AG | DOUBLED | $2.1M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $1.6M |
| PANAGORA ASSET MANAGEMENT INC | TRIM | $985.5K |
| RHUMBLINE ADVISERS | ADD | $502.8K |
| STRS OHIO | TRIM | $461.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
9 analystsPrice is below the lowest target. Median implies +297%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | B. Riley Securities REITERATE | Buy |
| Oct 26, 2026 | Chardan Capital MAINTAIN | Buy |
| Oct 22, 2026 | Chardan Capital MAINTAIN | Buy |
| Oct 5, 2026 | Chardan Capital MAINTAIN | Buy |
| Sep 28, 2026 | Rodman & Renshaw INITIATE | Buy |
| Sep 18, 2026 | Chardan Capital INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Wright Timothy Director Oct 1, 2026 | AWARD | 1,178.764 sh |
HARRISON THOMAS L Director Oct 1, 2026 | AWARD | $30.6K |
ARMEN GARO H See Remarks Aug 10, 2026 | AWARD | 1,971,500 sh |
Marcucci Marco Tullio Director Aug 5, 2026 | AWARD | 7,500 sh |
Hirsch Susan B Director Aug 5, 2026 | AWARD | 50,000 sh |
Buell Jennifer See Remarks Aug 5, 2026 | AWARD | 200,000 sh |
O'Day Steven J Chief Medical Officer Aug 5, 2026 | AWARD | 100,000 sh |
Wright Timothy Director Aug 5, 2026 | AWARD | 50,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.22 | -$0.22–-$0.22 | -650.0% | $30.9M |
| Next Q | -$0.15 | -$0.15–-$0.15 | No data | $23.2M |
| Current FY | $0.82 | $0.82–$0.82 | No data | $130.7M |
| Next FY | -$0.16 | -$0.16–-$0.16 | -45.5% | $123.2M |
Short side
FINRA· Oct 30, 2026SecBot reports
12 filings · 1 bullish · 4 bearish · 1 mixed · 6 neutral- NEUTRAL SC 13GNov 16, 2026
TCG Crossover GP III, LLC and related entities disclosed a 9.99% passive beneficial ownership stake in Agenus Inc via Schedule 13G, representing 4,954,779 shares (including common stock, pre-funded warrants, and Series B warrants exercisable within 60 days). The filing certifies no intent to…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 13, 2026
Eventide Asset Management disclosed a 5.4% passive stake in Agenus Inc via Schedule 13G…
Monitor for any future amendments that increase the stake above 5.4% or a conversion to Schedule 13D if the fund's intent changes. The passive nature and moderate size suggest limited near-term…
- NEUTRAL 8-KNov 5, 2026
Agenus reported Q3 2026 total revenue of $31.5M (up 4% YoY from $30.2M) and net income of $2.8M…
The key catalyst is the Phase 3 ROBBIN trial initiation in Q1 2027 and the interim pathologic response assessment of the first 100 patients expected in Q4 2027. The warrant milestones (60 patients…
- NEUTRAL 8-KAug 12, 2026
Agenus granted Chairman/CEO Garo Armen a one-time performance-based stock option award of…
This is a routine CEO compensation grant with no immediate trading signal. The performance hurdles are extremely high (3x-8x current stock price), making dilution unlikely in the near term. Monitor…
All AGEN filing & press-release reports (12)
- SC 13G reportNov 16, 2026
- SC 13G reportNov 13, 2026
- 8-K reportNov 5, 2026
- 8-K reportAug 12, 2026
- INST-CLUSTER reportAug 12, 2026
- S-3 reportAug 7, 2026
- 8-K reportAug 6, 2026
- S-3 reportJul 17, 2026
- 8-K reportJul 13, 2026
- COURT-RULING reportDec 4, 2025
- DEFA14A reportMay 13, 2026
- 8-K reportMay 11, 2026